Shares of CytomX Therapeutics, Inc. (NASDAQ:CTMX – Get Free Report) have been given a consensus rating of “Moderate Buy” by the twelve ratings firms that are currently covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, nine have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1 year target price among analysts that have updated their coverage on the stock in the last year is $11.90.
A number of research analysts have commented on CTMX shares. HC Wainwright cut their price target on shares of CytomX Therapeutics from $17.00 to $11.00 and set a “buy” rating for the company in a research note on Monday, May 11th. Weiss Ratings reiterated a “sell (d)” rating on shares of CytomX Therapeutics in a research note on Tuesday, June 16th. JPMorgan Chase & Co. dropped their target price on CytomX Therapeutics from $12.00 to $11.00 and set an “overweight” rating for the company in a report on Thursday, August 13th. Zacks Research downgraded CytomX Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, August 19th. Finally, Wall Street Zen downgraded CytomX Therapeutics from a “hold” rating to a “sell” rating in a research report on Sunday, August 23rd.
Read Our Latest Analysis on CytomX Therapeutics
CytomX Therapeutics Stock Performance
CytomX Therapeutics (NASDAQ:CTMX – Get Free Report) last released its quarterly earnings data on Thursday, August 6th. The biotechnology company reported ($0.09) EPS for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.01). The business had revenue of $1.42 million for the quarter, compared to the consensus estimate of $12.39 million. CytomX Therapeutics had a negative return on equity of 38.46% and a negative net margin of 435.21%. On average, sell-side analysts predict that CytomX Therapeutics will post -0.4 earnings per share for the current year.
Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently made changes to their positions in CTMX. Goldman Sachs Group Inc. acquired a new stake in shares of CytomX Therapeutics in the 1st quarter valued at $39,000. Woodline Partners LP acquired a new stake in shares of CytomX Therapeutics during the 1st quarter worth about $1,054,000. Geode Capital Management LLC increased its position in shares of CytomX Therapeutics by 103.4% during the 2nd quarter. Geode Capital Management LLC now owns 1,745,176 shares of the biotechnology company’s stock worth $3,963,000 after purchasing an additional 887,218 shares in the last quarter. Invesco Ltd. acquired a new stake in shares of CytomX Therapeutics during the 2nd quarter worth about $32,000. Finally, Marshall Wace LLP lifted its holdings in CytomX Therapeutics by 2,650.9% during the 2nd quarter. Marshall Wace LLP now owns 2,353,122 shares of the biotechnology company’s stock valued at $5,342,000 after purchasing an additional 2,267,583 shares during the last quarter. 67.77% of the stock is owned by institutional investors.
CytomX Therapeutics Company Profile
CytomX Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of next-generation therapeutics based on its proprietary Probody® platform. The company engineers masked antibody prodrugs that remain inactive in healthy tissue but are selectively activated in the tumor microenvironment. This approach is designed to enhance the safety and tolerability of antibody-based therapies, particularly those targeting immuno-oncology pathways.
At the core of CytomX’s pipeline is Pacmilimab (CX-072), an anti–PD-L1 Probody therapeutic currently undergoing clinical evaluation for multiple solid tumor indications.
Featured Stories
- Five stocks we like better than CytomX Therapeutics
- Revolution Medicines Got Its Breakthrough—What Moves It Next?
- Retail Earnings Just Exposed a Bigger Divide in the U.S. Consumer Economy
- FB Financial’s Southern Expansion and Buybacks Drive Analyst Optimism
- AST SpaceMobile Stock Soared 12%—This Was the Catalyst
Receive News & Ratings for CytomX Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytomX Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
